Buy Soliqua Solostar Pens Online

Soliqua Solostar Pens are prefilled diabetes pens that combine insulin glargine 100 units/mL with lixisenatide 33 mcg/mL. You can buy Soliqua Solostar Pens online, view the current displayed price, and match the Soliqua 100/33 SoloStar pen strength and 5 x 3 mL pack to the directions given by your clinician.

This combination medicine is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It is not the same as a basal insulin-only pen, because it also contains lixisenatide, a GLP-1 receptor agonist, an incretin-based medicine that can affect meal-related glucose control and stomach emptying.

Soliqua Solostar Pens Price and Pack Selection

Soliqua Solostar Pens price comparisons should begin with the exact strength, device, and carton quantity. This product is Soliqua 100/33 in SoloStar prefilled pens, supplied as 5 pens with 3 mL in each pen. The carton size is different from a single injected amount, so do not estimate a monthly total from the pack count alone.

The Soliqua Solostar cost shown during ordering can vary from insurance, reimbursement, or local pharmacy calculations. If you are assessing Soliqua 100/33 without insurance, separate the cash-pay amount from plan coverage questions. Handling charges, cold-chain requirements, and the number of cartons can also affect the final checkout total.

Strength and quantity matter because combination pens are not interchangeable with insulin-only products. Soliqua contains insulin glargine plus lixisenatide, while many nearby diabetes pens contain only insulin or only a non-insulin medicine. If you are browsing broader diabetes categories, the diabetes medications section can help you see how different treatment groups are organized.

Quick tip: Match the name, strength, device, and pack count before comparing totals.

How to Order Soliqua 100/33 Pens Online

To order Soliqua Solostar Pens online, choose the Soliqua 100/33 SoloStar pen and review the quantity before checkout. Keep the medicine name, concentration, and directions from your healthcare team nearby so the item you choose matches your treatment plan.

Use the active ingredients as the main identifier when similar pens appear in search or category browsing. The correct medicine combines insulin glargine 100 units/mL and lixisenatide 33 mcg/mL in a SoloStar prefilled pen. A pen with a similar shape, color, or insulin name may not contain the same combination.

Temperature-sensitive injectable medicines need practical delivery planning. Confirm that the address and contact details are accurate, and be available to receive a refrigerated package. Orders may use prompt, express, cold-chain shipping when appropriate, and the package should be inspected when it arrives.

If you are arranging US delivery from Canada, use the carton strength and quantity rather than country-specific packaging descriptions alone. Names, package images, and available presentations can vary by market, but the key buying decision is whether the Soliqua 100/33 pen and total mL align with your clinician’s instructions.

What Soliqua 100/33 Is Used For

Soliqua 100/33 is used along with diet and exercise to improve glycemic control in adults with type 2 diabetes. It combines a long-acting basal insulin with a GLP-1 receptor agonist, so it is intended for a specific treatment role rather than as a general substitute for any diabetes injection.

This medicine is not for type 1 diabetes and is not used to treat diabetic ketoacidosis. It is also not recommended for people with severe stomach-emptying problems. People with a history of pancreatitis should discuss that history with a healthcare professional before using GLP-1 receptor agonist therapy.

The type 2 diabetes collection can help you browse medicines related to the condition. Broader category browsing should not replace the exact medicine name, strength, and device specified for your care.

Active Ingredients and Pen Format

Each Soliqua 100/33 pen contains insulin glargine and lixisenatide. Insulin glargine is a long-acting insulin that helps lower blood glucose over an extended period. Lixisenatide is a GLP-1 receptor agonist that helps support glucose control through incretin-related effects, including effects around meals.

The SoloStar pen is a prefilled injector for subcutaneous injection, which means injection under the skin. The dose window uses dose steps for this specific combination medicine. The number shown on the pen should not be converted to a vial, cartridge, or another insulin pen without professional guidance.

Needle compatibility, injection technique, and rotation of injection sites are practical parts of safe pen use. General pen handling steps are covered in the insulin pen guide, while your own routine should follow the training provided by your healthcare team.

Storage, Handling, and Travel

Soliqua SoloStar pens are temperature-sensitive. Unused pens are generally stored in a refrigerator at 2°C to 8°C. Do not freeze the pens, and do not use any pen that has been frozen. Keep the carton protected from direct heat and light.

After first use, follow the label instructions for room-temperature storage and discard the pen after 28 days, even if medicine remains. Do not store the pen with a needle attached. Removing the needle after each injection helps reduce leakage, air entry, clogging, and contamination risk.

Inspect the medicine before each injection. The solution should be clear and colorless. Do not use a pen if the liquid is cloudy, colored, contains particles, or appears damaged. If a pen has been exposed to extreme temperature, ask a healthcare professional or pharmacist before using it.

Travel can expose injectable medicines to temperature swings. Keep the pen in a temperature-protected case, avoid direct contact with ice packs, and carry medicine supplies together. Airport screening, parked cars, and hotel refrigerators can create storage problems if the medicine is not protected.

Why it matters: Temperature damage can affect medicine quality before the carton looks unusual.

Side Effects, Warnings, and Monitoring

Soliqua can cause low blood sugar, especially when meals, activity, illness, alcohol use, or other glucose-lowering medicines change. Symptoms may include shakiness, sweating, hunger, headache, dizziness, fast heartbeat, confusion, or weakness. Severe hypoglycemia can require urgent treatment.

Do not use this medicine during episodes of hypoglycemia or if you have had a serious hypersensitivity reaction to insulin glargine, lixisenatide, or any ingredient in the product. Serious allergic reactions can include swelling, rash, trouble breathing, or severe dizziness. Seek urgent help if those symptoms occur.

Common side effects can include nausea, diarrhea, vomiting, headache, and injection-site reactions. Gastrointestinal effects may be more noticeable when treatment begins or after changes in therapy. Ongoing vomiting or diarrhea can increase dehydration risk and may affect kidney function.

Pancreatitis has been reported with GLP-1 receptor agonists. Severe abdominal pain that may spread to the back, especially with vomiting, needs prompt clinical attention. Gallbladder problems have also been reported with this medicine class. Symptoms such as right upper abdominal pain, fever, clay-colored stools, or yellowing skin should be evaluated.

Because this medicine contains insulin, low potassium can occur. The risk may be higher when used with other medicines that lower potassium. Fluid retention and heart failure can be a concern when insulin is used with thiazolidinediones, a class that includes pioglitazone and rosiglitazone.

Monitoring often includes home blood glucose checks and periodic A1C testing. A healthcare professional may also consider kidney function, hydration status, weight changes, potassium levels, gastrointestinal tolerance, and injection-site problems. If glucose readings become unusually high or low, record timing, meals, activity, and other medicines before contacting your care team.

Interactions and Use Considerations

Give your healthcare team a current list of diabetes medicines, heart medicines, diuretics, steroids, antibiotics, supplements, and over-the-counter products. Some medicines can raise blood sugar, while others increase the chance of hypoglycemia. Beta blockers may make certain low-blood-sugar warning signs harder to notice.

Lixisenatide can slow stomach emptying, which may affect how quickly some oral medicines are absorbed. Ask how to time medicines that must be taken on a strict schedule. Do not combine this pen with another GLP-1 receptor agonist unless a healthcare professional has specifically directed that plan.

Soliqua is not usually evaluated as an add-on to prandial, or mealtime, insulin. Combining basal insulin, mealtime insulin, sulfonylureas, or GLP-1 therapy without a clear plan can increase side effect risk and make glucose patterns harder to interpret.

Ask for clinical guidance before using this combination pen if you are pregnant, planning pregnancy, breastfeeding, have kidney disease, have severe stomach problems, or have a history of pancreatitis. These factors may affect whether this medicine remains appropriate for you.

How It Differs From Other Diabetes Pens

A substitute for Soliqua is not a simple pen swap. This medicine combines basal insulin with a GLP-1 receptor agonist, so alternatives may differ by active ingredient, concentration, device, side effect profile, and dosing approach. Similar-looking pens can have very different clinical roles.

Basal insulin products are organized separately in the long-acting insulin category. Those medicines may help with background insulin needs, but they do not provide the lixisenatide component found in Soliqua.

GLP-1 receptor agonists are also a distinct group. The GLP-1 agonists category can help you understand where non-insulin incretin-based medicines sit within diabetes treatment. Soliqua remains a combination pen, not a stand-alone GLP-1 injection.

The broader insulin medications category may be useful when comparing insulin classes, device types, and treatment roles. Use these categories for orientation only; the medicine you choose should match the exact combination, strength, and quantity intended for your care.

Authoritative Sources

Official prescribing information summarizes labeled use, contraindications, warnings, storage, and pen handling: SOLIQUA 100/33 prescribing information.

Use the official label when questions involve storage limits, missed-dose instructions, severe side effects, contraindications, or whether another diabetes medicine can be used with this combination pen.

The diabetes articles section and type 2 diabetes articles can provide additional background on diabetes care topics, but individualized treatment decisions should come from a qualified healthcare professional.

This content is for informational purposes only and is not a substitute for professional medical advice.